title: Prediction of medication noncompliance in outpatients with schizophrenia: 2-year follow-up study.
abstract: Neuroleptic noncompliance is a major reason for relapse in outpatients with schizophrenia. In a 2-year follow-up study, we used the Japanese version of the Rating of Medication Influences Scale (ROMI-J) to investigate the reasons for compliance and noncompliance in outpatients with schizophrenia. Ninety outpatients who were confirmed by interview to have had good compliance for more than 3 months completed the initial interview, which included the Clinical Global Impressions Scale (CGI), the Brief Psychiatric Rating Scale (BPRS), the Global Assessment of Functioning Scale (GAF), the UKU Side Effect Rating Scale, and the ROMI-J. All the outpatients were followed up for 2 years. At the initial interview, the most frequent reason for compliance was "relapse prevention," while the most frequent reason for noncompliance was "distressed by side effects." Fifteen outpatients who proved to be noncompliant in the follow-up period had higher baseline BPRS "agitation" scores and ROMI-J "no perceived daily benefit" ratings than compliant patients. Sixty-four outpatients who maintained compliance during the follow-up had higher baseline ROMI-J ratings of "fulfillment of life goals" than their noncompliant counterparts. It is important to understand the attitudes of patients with schizophrenia toward drug therapy in order to predict better compliance and provide psychoeducation designed to forestall relapses.
authors.affiliation: Department of Psychiatry, Tokyo Women's Medical University, Medical Center East, 2-1-10 Nishi-ogu, Arakawa-ku, Tokyo 116-8567, Japan. yamadaps@dnh.twmu.ac.jp
authors.forename: Kazuo
authors.initials: K
authors.lastname: Yamada
authors.forename: Koichiro
authors.initials: K
authors.lastname: Watanabe
authors.forename: Naoyuki
authors.initials: N
authors.lastname: Nemoto
authors.forename: Hidechika
authors.initials: H
authors.lastname: Fujita
authors.forename: Chikayo
authors.initials: C
authors.lastname: Chikaraishi
authors.forename: Keita
authors.initials: K
authors.lastname: Yamauchi
authors.forename: Gohei
authors.initials: G
authors.lastname: Yagi
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asai
authors.forename: Shigenobu
authors.initials: S
authors.lastname: Kanba
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000553:Ambulatory Care; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001294:Attitude to Health; D010054:Brief Psychiatric Rating Scale; D005260:Female; D005500:Follow-Up Studies; D015438:Health Behavior; D006801:Humans; D007406:Interview, Psychological; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012559:Schizophrenia / Q000175:diagnosis / Q000188:drug therapy / Q000628:therapy*; D011795:Surveys and Questionnaires; D016312:Treatment Refusal / Q000706:statistics & numerical data*
chemical_list: D014150:Antipsychotic Agents